Related Experiment Video

Updated: Oct 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia

R Alonso1, P Mata, R De Andres

  • 1Lipid Research Unit, Department of Internal Medicine, Fundación Jiménez Díaz, Madrid, Spain.

Atherosclerosis
|July 27, 2001
PubMed

Insights

Long-term simvastatin treatment significantly improved arterial endothelial function and reduced soluble E-selectin levels in patients with heterozygous familial hypercholesterolemia (hFH). This study highlights simvastatin

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Patients with heterozygous familial hypercholesterolemia (hFH) face a high risk of premature coronary heart disease.
  • Statins have demonstrated efficacy in reducing cardiovascular mortality in hFH patients.
  • Endothelial dysfunction is a key factor in the pathogenesis of atherosclerosis and cardiovascular events.

Purpose of the Study:

  • To evaluate the long-term effects of simvastatin on arterial endothelial function, specifically flow-mediated dilatation (FMD).
  • To assess changes in soluble E-selectin (sE-selectin) levels, a marker of endothelial activation, in hFH patients undergoing lipid-lowering therapy.

Main Methods:

  • Twenty-five hFH patients received simvastatin for 52 weeks, targeting at least a 30% reduction in LDL-cholesterol (LDL-C).
  • Endothelial function was assessed by brachial artery flow-mediated dilatation (FMD) using vascular ultrasound.
  • Biochemical markers, including sE-selectin, tumor necrosis factor-alpha (TNF-alpha), and interleukin-6, were measured using ELISA.

Main Results:

  • Simvastatin treatment led to a significant reduction in LDL-C levels (43-44%) sustained throughout the 52-week study period.
  • A significant improvement in endothelial function was observed, with FMD increasing from baseline (4.7%) to 12 weeks (12.3%) and 52 weeks (9.7%).
  • Soluble E-selectin levels decreased significantly from baseline (16.2 ng/ml) at 12 weeks (11.0 ng/ml) and were maintained at 52 weeks (12.3 ng/ml).

Conclusions:

  • Long-term simvastatin therapy demonstrates a sustained beneficial effect on endothelial function in hFH patients.
  • The observed improvement in FMD and reduction in sE-selectin suggest a protective role of simvastatin against endothelial dysfunction in this high-risk population.
  • These findings support the continued use of statins for managing cardiovascular risk in patients with heterozygous familial hypercholesterolemia.

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...